Zonisamide in the treatment of bulimia nervosa: An open-label, pilot, prospective study


    loading  Checking for direct PDF access through Ovid

Abstract

Objective:To assess preliminarily the effectiveness of zonisamide in bulimia nervosa.Method:This was an open-label, prospective, 12-week, flexible dose study of zonisamide in bulimia nervosa. The primary outcome was binge-purge episode frequency.Results:Twelve individuals received zonisamide, 10 completed at least one post-baseline evaluation, and six completed the study. Mean dose at endpoint was 420 (SD = 215) mg/day. Zonisamide was associated with significant reductions in frequency of binge-purge episodes and binge-purge days as well as measures of binge eating behavior, purging behavior, clinical severity, obsessive-compulsive features, and depressive symptoms. Weight was unchanged.Discussion:In this open-label trial, zonisamide was effective in bulimia nervosa, but associated with a high discontinuation rate. © 2013 Wiley Periodicals, Inc. (Int J Eat Disord 2013; 46:747–750)

    loading  Loading Related Articles